Pazopanib is an approved treatment for renal cell carcinoma and a second-line treatment for
nonadipocytic soft-tissue sarcoma. However, its clinical efficacy is limited by its …

Aim Vascular endothelial growth factor (VEGF) is an angiogenic factor whose production is
increased in pre‐eclampsia (PE). Therefore, the present study was conducted aiming at …

Background Bevacizumab is a beneficial therapy in several advanced cancer types.
Predictive biomarkers to better understand which patients are destined to benefit or …

Cancer treatment is an area of continuous improvement. Therapy is becoming more targeted
and the use of anti-angiogenic agents in multiple cancers, specifically tyrosine kinase …

Cardiac toxicity of molecularly targeted cancer agents is increasingly recognized as a
significant side effect of chemotherapy. These new potent therapies may not only affect the …

Vascular endothelial growth factor (VEGF) is a mitogen that plays a crucial role in
angiogenesis and lymphangiogenesis. It is involved in tumor survival through inducing …

Angiogenesis is a key process involved in both cancer and cardiovascular diseases, the
vascular endothelial growth factor (VEGF) and its VEGF receptor-2 (VEGFR-2) being the …

Patients with cancer are frequently exposed to risk of renal injuries associated with disease-
related or iatrogenic causes. Nephrotoxicity is a potential adverse effect of anti-cancer …

Severe acute arterial hypertension can be associated with significant morbidity and
mortality. After excluding a reversible etiology, choice of therapeutic intervention should be …

Abstract Purpose of Review With increasing survival after cancer treatment, there is a need
for long-term management of risk factors and chronic medical conditions to realize the full …